Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Shares, with no par value
-
Shares outstanding
-
50,973,571
-
Total 13F shares
-
12,813,323
-
Share change
-
+10,843,247
-
Total reported value
-
$75,287,324
-
Price per share
-
$5.90
-
Number of holders
-
27
-
Value change
-
+$63,953,896
-
Number of buys
-
22
-
Number of sells
-
4
Institutional Holders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) as of Q3 2025
As of 30 Sep 2025,
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,813,323 shares.
The largest 10 holders included
Beutel, Goodman & Co Ltd., Vivo Capital, LLC, Balyasny Asset Management L.P., SCOTIA CAPITAL INC., GREAT POINT PARTNERS LLC, Ally Bridge Group (NY) LLC, Logos Global Management LP, ROYAL BANK OF CANADA, Velan Capital Investment Management LP, and Affinity Asset Advisors, LLC.
This page lists
27
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.